Scott A. Smith is the chief executive officer of Viatris and a member of the company’s board of directors. He will lead the execution of the company’s previously announced Phase 2 strategic plan designed to guide Viatris into a period of renewed growth.
Smith is a deeply knowledgeable senior global biotechnology and pharmaceutical executive with more than 35 years of experience. He is a seasoned builder who possesses vast global commercial and pharmaceutical expertise and a proven ability to build, grow and manage large complex organizations. He also has substantial experience in developing and executing regulatory, clinical, and business development strategies.
Before becoming Viatris’ CEO, Smith was President of BioAtla, Inc., a global biotechnology company focused on the development of Conditionally Active BiologicsTM (CAB) antibody therapeutics. He is a member of the BioAtla board of directors and is Chairman of the board of Triumvira Immunologics.
Smith previously served on the boards of directors of Refuge Biotechnologies, Inc., of Titan Pharmaceuticals, Inc., chairing the Compensation and Nominating and Governance Committees; and as Chairman of F-star Therapeutics, Inc., serving on that company’s Audit and Nominating and Corporate Governance Committees.
Previously, Smith was President and Chief Operating Officer at Celgene Corporation, rising up the ranks from SVP and Global Head of Immunology, and then President of Inflammation and Immunology. One of his many achievements during his 10-year career at Celgene was to build and oversee the clinical development, registration, launch and global commercial success of the blockbuster drug Otezla®.
He holds a BSc in Chemistry and Biology as well as an HBSc in Pharmacology and Toxicology from the University of Western Ontario and received his master’s degree in International Management from the American Graduate School of International Management (Thunderbird).